Class action lawsuit says Dexcom sold G7 glucose monitors that failed to warn of life-threatening glucose levels

Dexcom class action lawsuit overview:

• Who: Plaintiff Kelly Grisoli filed a class action lawsuit against Dexcom Inc.
• Why: Grisoli claims Dexcom manufactured, marketed and sold defective glucose monitors, which she purchased for her diabetic son.
• Where: The Dexcom class action lawsuit was filed in California federal court.

A new class action lawsuit accuses Dexcom of manufacturing, marketing and selling defective glucose monitors that are prone to dangerous alert failures.

Plaintiff Kelly Grisoli says she relied on Dexcom’s marketing claims when she purchased the G7 glucose monitor for her diabetic son. According to the Dexcom class action lawsuit, the device failed to perform as promised — often giving inaccurate glucose readings and missing critical alerts — forcing her to rely on fingerstick tests to verify results.

Grisoli also claims the G7 sensors failed to last the advertised 10-day wear period, sometimes malfunctioning after just two days and requiring frequent replacements. When she requested help, Dexcom allegedly threatened to deny replacements, saying she had ordered too many in one month.

The Dexcom class action lawsuit further alleges the company falsely marketed the G7 Continuous Glucose Monitoring System as a superior, FDA-approved medical device that would “continuously and accurately track glucose levels.” In reality, Grisoli says, the devices are defective and put users at risk of severe hypoglycemia, hyperglycemia, seizures, coma or death due to inaccurate readings and delayed or failed alerts.

Dexcom allegedly continued to market defective glucose monitors

Dexcom recalled the G7 glucose monitors in June and September, Grisoli claims, after the FDA announced nationwide Class I recalls for the devices due to safety issues that caused failures or delays in providing critical low- or high-glucose alerts.

Grisoli claims Dexcom continued to market and sell the G7 glucose monitors despite knowing they were defective.

“Consumers, including Plaintiff and Class Members, paid a substantial premium for the G7 CGM based on these misrepresentations and omissions, only to receive a product that failed to perform as promised, was subject to government recall and posed a serious safety risk,” the Dexcom class action lawsuit says.

Grisoli claims Dexcom is guilty of violating multiple consumer protection and warranty statutes, including California’s Consumers Legal Remedies Act, Unfair Competition Law and False Advertising Law, as well as express and implied warranty provisions under state and federal law.

Grisoli demands a jury trial and requests declaratory judgment and an award of actual, compensatory and punitive damages for herself and all class members.

In 2024, Tandem Diabetes Care recalled its t:connect mobile app for Apple iOS, used with the t:slim X2 insulin pump, after reports that the app could crash, leading to battery drain and under-delivery of insulin.

Have you ever purchased a Dexcom G7 glucose monitor? Let us know in the comments.

The plaintiff is represented by C. Moze Cowper and Paige Miller of Cowper Law LLP and Adam J. Levitt of DiCello Levitt LLC.

The Dexcom class action lawsuit is Grisoli v. Dexcom Inc., Case No. 8:25-cv-02333, in the U.S. District Court for the Central District of California.

Read About More Class Action Lawsuits & Class Action Settlements:

• Class action alleges On Cloud shoes have defect that causes them to squeak
• Class action claims Hawaiian Tropic’s ‘SPF 50’ sunscreen provides far less protection
• Campbell Soup faces class action for misleading ‘natural’ labeling on V8 Energy products
• Arkansas Federal Credit Union class action alleges improper overdraft fees